Huada Gene (300676.SZ) released its 2023 annual performance report. During the reporting period, the company is expected to operate...
According to the Zhitong Finance App, Huada Gene (300676.SZ) released its 2023 annual performance report. During the reporting period, the company expects to achieve operating income of 4.353 billion yuan, down 38.29% from the same period last year; net profit attributable to shareholders of listed companies is expected to be 91.121 million yuan, down 88.64% from the same period last year.
During the reporting period, the company's performance declined significantly compared to 2022. Mainly during the reporting period, due to the industry cycle, the company's related testing business revenue declined significantly. During the reporting period, the company continued to proactively and strategically adjust the product structure and supply chain strategy of its main business to promote the steady development of its main business. Among them, revenue from the reproductive health business and the multiomics business increased slightly year-on-year, and revenue from cancer prevention and control achieved significant year-on-year growth. The company continues to carry out “lean management, improve quality and efficiency” to strengthen cost and expense control and improve operational efficiency. At the same time, it actively responds to market changes, increases investment in R&D resources, and maintains continuous product and technological innovation. The share of the company's R&D investment in revenue during the reporting period increased significantly compared to 2022.